Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.36 |
| ▸ | AHR | P35869 | 3/20 | 0.36 |
| ▸ | C1R | P00736 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3613930 | 0.84 | ELANE (0.51) | PSMB8PSMB5MAPTNPC1RAB9A | |
| SCHEMBL7899508 | 0.81 | LOXL2 (0.56) | PSMB8PSMB5MAPTALDH1A1NPC1 | |
| SCHEMBL9846370 | 0.80 | ELANE (0.43) | MAPTKDM4EALDH1A1MTNR1AMTNR1B | |
| SCHEMBL21685060 | 0.80 | MAPT (0.40) | PSMB8PSMB5MAPTKDM4EALDH1A1 | |
| SCHEMBL9846250 | 0.80 | PIK3CD (0.43) | MAPTKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL20964583 | 0.80 | ELANE (0.55) | PSMB8PSMB5MAPTALDH1A1MTNR1A | |
| SCHEMBL102232 | 0.78 | PSMB8 (0.50) | PSMB8PSMB5MAPTNPC1RAB9A | |
| SCHEMBL5535332 | 0.77 | PSMB8 (0.56) | PSMB8PSMB5MAPTKDM4EALDH1A1 | |
| SCHEMBL3954800 | 0.76 | PSMB8 (0.59) | PSMB8PSMB5ALDH1A1NPC1RAB9A | |
| SCHEMBL23932555 | 0.76 | ALDH1A1 (0.40) | MAPTKDM4EALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| WO-2007015809-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
| EP-0462800-A2 | Inhibitors of HIV reverse transcriptase | MERCK & CO. INC. (US) | 1991-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | PSMB8 1039/4885PSMB5 2041/4885MAPT 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.